Yahoo Finance

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...
Forbes

More Than 40 Million Americans Have Now Attended College Without Earning A Degree

As of July 2021, 40.4 million Americans have attended college but stopped out before earning any credential. That’s a 3.6% increase, equal to 1.4 million more “some college, no credential” (SCNC) ...
Yahoo Finance

COLLEGE STUDENT “STOP-OUT” POPULATION INCREASED 3.6% FROM PREVIOUS YEAR

Herndon, VA, April 25, 2023 (GLOBE NEWSWIRE) -- The National Student Clearinghouse Research Center announced today that the “some college, no credential” (SCNC) population–former students who stopped ...
ascopubs.org

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? Patients with progressive, metastatic castration-resistant prostate cancer ...
ascopubs.org

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell ...

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. This is an ASCO Meeting ...